Anti-BRCA1

Anti-BRCA1

Upstate (Millipore)

Recognizes human BRCA1.

220 kDa

GST-tagged fusion protein corresponding to amino acids 1301-1863 of human BRCA1.

IgG

Two major susceptibility genes for breast cancer, BRCA1 and BRCA2, have been identified. Both genes are considered to be tumor-suppressor genes. Mutations within BRCA1 and BRCA2 are responsible for most familial breast cancer cases. Functional analyses of the BRCA1 and BRCA2 gene products have established their dual participation in transcription regulation and DNA damage repair. BRCA1 affects cell cycle regulation and loss of BRCA1 function due to decreased expression leads to cell cycle arrest, through p53 and p21 genes. In vivo, BRCA1 and BRCA2 are expressed at maximal levels in rapidly proliferating cells. This feature is consistent with in vitro observations that BRCA1 and BRCA2 are expressed in a cell cycle-dependent manner. During mammary gland development, the expression of BRCA1 and BRCA2 is induced in rapidly proliferating cellular compartments.

Human

Positive Control Included: HeLa Nuclear Extract (12-309). Other controls: MCF-7 cell lysate

routinely evaluated by immunoblot in HeLa nuclear extract

Unpurified

Serum containing 0.035% sodium azide and 30% glycerol. Liquid at -20°C.

Maintain for 2 years at -20°C from date of shipment. Aliquot to avoid repeated freezing and thawing. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap.

P38398

NM_007294

• BRCA1
• RNF53
• BRCAI
• PSCP
• BRCC1
• IRIS

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

This gene encodes a nuclear phosphoprotein that plays a role in maintaining genomic stability and acts as a tumor suppressor. The encoded protein combines with other tumor suppressors, DNA damage sensors, and signal transducers to form a large multi-subunit protein complex known as BASC for BRCA1-associated genome surveillance complex. This gene product associates with RNA polymerase II, and through the C-terminal domain, also interacts with histone deacetylase complex. This protein thus plays a role in transcription, DNA repair of double-stranded breaks, and recombination. Mutations in this gene are responsible for approximately 40% of inherited breast cancers and more than 80% of inherited breast and ovarian cancers. Alternative splicing plays a role in modulating the subcellular localization and physiological function of this gene. Many alternatively spliced transcript variants have been described for this gene but only some have had their full-length natures identified.

• Immunohistochemistry
• Immunoprecipitation
• Western Blotting

FUNCTION: SwissProt: P38398 # Plays a central role in DNA repair by facilitating cellular response to DNA repair. Required for appropriate cell cycle arrests after ionizing irradiation in both the S-phase and the G2 phase of the cell cycle. Involved in transcriptional regulation of P21 in response to DNA damage. Required for FANCD2 targeting to sites of DNA damage. May function as a transcriptional regulator. Mediates E2-dependent ubiquitination. Inhibits lipid synthesis by binding to inactive phosphorylated ACACA and preventing its dephosphorylation.
SIZE: 1863 amino acids; 207721 Da
SUBUNIT: Part of the BRCA1-associated genome surveillance complex (BASC), which contains BRCA1, MSH2, MSH6, MLH1, ATM, BLM, PMS2 and the RAD50-MRE11-NBN protein complex. This association could be a dynamic process changing throughout the cell cycle and within subnuclear domains. CTIP interacts specifically with the BRCT domains. Interacts with RNA polymerase II holoenzyme. Interacts with SMC1A and COBRA1/NELFB. Binds BRIP1 through the BRCT domains. Interacts with ubiquitinated FANCD2. Interacts with BAP1. Interacts with DCLRE1C/Artemis and CLSPN. Interacts with histone H2AFX and this requires phosphorylation of H2AFX on 'Ser-139'. Interacts with CHEK1/CHK1. Interacts with BRCC3. Interacts through its BRCT domains with phosphorylated ACACA and prevents its dephosphorylation.
SUBCELLULAR LOCATION: Nucleus.
DOMAIN: SwissProt: P38398 The RING-type zinc finger domain interacts with BAP1.
PTM: Phosphorylated in response to IR, UV, and various stimuli that cause checkpoint activation, probably by ATM or ATR.
DISEASE: "SwissProt: P38398 # Defects in BRCA1 are a cause of genetic susceptibility to breast cancer (BC) [MIM:113705, 114480]. BC is an extremely common malignancy, affecting one in eight women during their lifetime. A positive family history has been identified as major contributor to risk of development of the disease, and this link is striking for early-onset breast cancer. Mutations in BRCA1 are thought to be responsible for 45% of inherited breast cancer. Moreover, BRCA1 carriers have a 4-fold increased risk of colon cancer, whereas male carriers face a 3-fold increased risk of prostate cancer. Cells lacking BRCA1 show defects in DNA repair by homologous recombination. & Defects in BRCA1 are a cause of genetic susceptibility to breast-ovarian cancer (BOC) [MIM:113705]. Mutations in BRCA1 are thought to be responsible for more than 80% of inherited breast- ovarian cancer. & Defects in BRCA1 are a cause of genetic susceptibility to ovarian cancer [MIM:113705]."
SIMILARITY: Contains 2 BRCT domains. & Contains 1 RING-type zinc finger.

100 μL

Upstate

Serum

Rabbit

Anti-BRCA1

Variable

Polyclonal Antibody